Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

Détails

ID Serval
serval:BIB_BD9982B15939
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
Périodique
AIDS Research and Human Retroviruses
Auteur(s)
Bures  R., Gaitan  A., Zhu  T., Graziosi  C., McGrath  K. M., Tartaglia  J., Caudrelier  P., El Habib  R., Klein  M., Lazzarin  A., Stablein  D. M., Deers  M., Corey  L., Greenberg  M. L., Schwartz  D. H., Montefiori  D. C.
ISSN
0889-2229 (Print)
Statut éditorial
Publié
Date de publication
12/2000
Volume
16
Numéro
18
Pages
2019-35
Notes
Clinical Trial
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S. --- Old month value: Dec 10
Résumé
Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1(MN)gp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.
Mots-clé
AIDS Vaccines/*immunology Adult Amino Acid Sequence Avipoxvirus/*genetics Cell Membrane/metabolism Genetic Vectors HIV Antibodies/biosynthesis/blood/*immunology HIV Envelope Protein gp120/genetics/*immunology/metabolism HIV Envelope Protein gp160/genetics/*immunology/metabolism HIV Infections/*prevention & control HIV-1/*immunology Heteroduplex Analysis Humans Immunization, Secondary Male Middle Aged Molecular Sequence Data Neutralization Tests Peptides/chemistry/immunology Phylogeny Vaccination Vaccines, Synthetic/immunology
Pubmed
Web of science
Création de la notice
25/01/2008 14:58
Dernière modification de la notice
20/08/2019 15:31
Données d'usage